Welcome to our dedicated page for Izotropic Canada news (Ticker: IZOZF), a resource for investors and traders seeking the latest updates and insights on Izotropic Canada stock.
Izotropic Corporation (OTCQB: IZOZF) is a medical device company developing the IzoView Breast CT Imaging System and related imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers. The Izotropic news feed on Stock Titan brings together company announcements and third-party coverage that explain how the company is advancing its breast imaging technology and commercialization plans.
News items for Izotropic often highlight progress around the IzoView Breast CT Imaging System, including the integration of a patent-pending radiation dose personalization feature that uses an optical pre-scan and proprietary software to calculate patient-specific radiation doses. Other coverage discusses the system’s compression-free, contact-free design and its focus on improving detection accuracy in women with dense breast tissue.
Investors and healthcare stakeholders can also find updates on Izotropic’s AI integration, such as its trade-secret machine-learning reconstruction algorithm, proprietary deep-learning reconstruction algorithm for image optimization, and exclusive rights to a U.S. patent for computer-aided diagnosis (CADx) with breast CT technology. Editorial features and interviews explore how these capabilities position IzoView within the evolving field of AI-enabled breast imaging.
Additional news includes the launch of educational resources like the BreastCT.com “Breast Imaging News” section, a podcast series on AI and the future of breast imaging, and a corporate FAQ page designed to improve transparency for investors, analysts, and healthcare decision-makers. Governance and corporate updates, such as Annual General and Special Meeting results and by-law amendments, also appear in the company’s news flow. Bookmark this page to review Izotropic’s ongoing disclosures, educational initiatives, and media coverage related to its breast imaging technology.
Izotropic Corporation (OTCQB: IZOZF) was featured in CEO.CA's "Inside the Boardroom" interview on October 21, 2025, where CEO Robert Thast discussed the company's breast cancer technology and strategy.
The interview positions the technology as targeting 50% of women currently underserved by existing screening or diagnostic options and invites investors to view the full conversation via CEO.CA and YouTube. The piece also promotes CEO.CA as an investor social network with broad engagement and weekly executive interviews.
Izotropic (OTCQB: IZOZF) highlighted gaps in current breast imaging during Breast Cancer Awareness Month and positioned its IzoView Breast CT as a dedicated, true 3D adjunct for screening asymptomatic women with dense breasts. The company cited screening limits: ~20% cancers missed at mammography, 10–12% false negatives, and up to 50–60% of women experiencing a false positive within 10 years. Izotropic described IzoView as acquiring ~500 high-resolution images in ~10 seconds, reconstructing a true 3D volume, and targeting a device sales price of USD $500,000. The firm referenced market growth from USD $5.4B (2024) to $8.69B (2030, CAGR 8.25%) and research claims of breast CT offering markedly higher spatial resolution than MRI.
Izotropic (OTCQB: IZOZF) has published a new article on BreastCT.com highlighting the competitive advantages of its IzoView Breast CT Imaging System in AI-integrated breast imaging. The article emphasizes IzoView's purpose-built design for artificial intelligence integration, featuring a proprietary reconstruction algorithm and compression-free scanning capability that delivers high-quality 3D images in just 10 seconds.
The system, targeted at a USD $500K price point, addresses growing demand for advanced breast screening solutions, particularly for dense breast tissue. IzoView's architecture combines exclusive AI capabilities with scalable software features, positioning it as a future-ready platform in the evolving landscape of intelligent medical imaging.
["Purpose-built design for AI integration with proprietary reconstruction algorithm", "Fast 10-second compression-free scanning capability", "Competitive USD $500K target price point", "Specifically addresses dense breast tissue screening challenges"]Izotropic (OTCQB: IZOZF) has announced a groundbreaking advancement for its IzoView Breast CT Imaging System, introducing the first-ever patent-pending radiation dose personalization feature in breast CT systems. The system utilizes a radiation-free optical pre-scan technology to customize radiation doses based on individual breast size and composition.
The innovation comes as the global breast imaging market is projected to grow from $5.4 billion in 2024 to $8.69 billion by 2030. IzoView is advancing through the FDA's Pre-Market Approval process and plans a dual-path strategy for both U.S. and European market entry, leveraging data from its upcoming U.S. clinical study for CE Mark submission.
Izotropic Corporation (OTCQB: IZOZF) has launched a new FAQ webpage at www.izocorp.com/faq to enhance transparency and provide comprehensive information about its IzoView Breast CT Imaging System. The resource serves multiple stakeholders including investors, analysts, and healthcare professionals.
The FAQ page covers key topics such as IzoView's advantages over traditional imaging methods (mammography, tomosynthesis, ultrasound, and MRI), breast density's role in cancer detection, and the company's exclusive global commercialization rights for breast CT technology from UC Davis. The page is optimized for search engines and AI platforms to improve visibility across various channels.
Izotropic Corporation (OTCQB: IZOZF) has gained visibility in the expanding AI market through a sponsored editorial placement on MarketScreener.com. The article positions Izotropic as part of the next wave of AI innovation, focusing on specialized AI applications in healthcare.
The editorial highlights how AI is evolving beyond general applications to address specific industry challenges, particularly in healthcare, enterprise software, defense, and industrial automation. Izotropic's IzoView technology, which is approaching commercialization, is presented as a potential new standard in breast cancer imaging, combining disruptive technology with a strong IP portfolio.
Izotropic Corporation (OTCQB: IZOZF) has secured exclusive U.S. patent rights for computer-aided diagnosis (CADx) with breast CT technology through a global license agreement with the University of California. The company's flagship device, IzoView Breast CT Imaging System, is being developed as a 3D breast imaging solution positioned between Digital Breast Tomosynthesis (DBT) and MRI.
While IzoView will initially launch without CADx functionality, it will include a proprietary machine-learning image reconstruction algorithm that optimizes images while maintaining low radiation doses. The CADx feature will be integrated post-market launch as a software upgrade, potentially serving as an incentive for early adopters and creating future revenue opportunities.
Izotropic Corporation (OTCQB: IZOZF) has announced a significant AI breakthrough in breast CT imaging with its proprietary machine-learning reconstruction algorithm integration into the IzoView Breast CT Imaging System. The algorithm, developed in collaboration with Johns Hopkins University School of Medicine, enhances image quality while maintaining low radiation doses.
The company's innovative AI solution addresses key limitations of existing CT denoising methods like Model-Based Iterative Reconstruction (MBIR) and Deep Machine-Learning Reconstruction (DMLR). The algorithm works on raw X-ray data before reconstruction, enabling faster processing and consistent image optimization at low radiation doses.
Trained on 15 years of specialized breast CT data and protected as a trade secret, the technology provides Izotropic with a significant competitive advantage in the breast CT imaging market.
Izotropic Corporation (OTCQB: IZOZF) has launched BreastCT.com, a comprehensive educational platform focused on breast CT technology and the company's IzoView Breast CT Imaging System. The website aims to educate about dedicated breast CT technology, particularly highlighting its potential in addressing breast cancer detection challenges for the 50% of women with dense breast tissue.
With IzoView's engineering phase now complete, the platform will evolve through clinical studies, regulatory phases, and commercial launch preparations. The site also contextualizes Izotropic's position by featuring successful public companies that have established new imaging categories, helping build market recognition ahead of future milestones.
Izotropic Corporation (OTCQB: IZOZF), a medical device company focused on breast cancer imaging technology, has unveiled its new corporate website and brand identity. The redesigned website, izocorp.com, showcases the company's refined positioning and modern visual identity, emphasizing its focus on patients, clinicians, and healthcare stakeholders.
The company introduced two new taglines: "Advanced Imaging. Accessible Care." for corporate communications, and "Engineered for Today's Challenges and Tomorrow's Care Models" for their flagship IzoView Breast CT Imaging System. The updated website features enhanced navigation, new presentations, and video materials highlighting Izotropic's value proposition and strategic direction toward commercialization.